Open Access
Lenalidomide induces degradation of IKZF1 and IKZF3
2
Boston, MA USA.
|
Publication type: Journal Article
Publication date: 2014-07-03
scimago Q1
wos Q1
SJR: 2.542
CiteScore: 12.9
Impact factor: 6.3
ISSN: 21624011, 2162402X
PubMed ID:
25610725
Oncology
Immunology
Immunology and Allergy
Abstract
Lenalidomide and its analogs, thalidomide and pomalidomide, specifically inhibit growth of mature B-cell lymphomas, including multiple myeloma, and induce interleukin-2 (IL-2) release from T cells. We recently found that this results from activation of the CRBN-CRL4 E3 ubiquitin ligase to degrade the lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos).
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
|
|
|
Journal of Medicinal Chemistry
3 publications, 3.66%
|
|
|
International Journal of Molecular Sciences
2 publications, 2.44%
|
|
|
Frontiers in Immunology
2 publications, 2.44%
|
|
|
European Journal of Medicinal Chemistry
2 publications, 2.44%
|
|
|
Cell Chemical Biology
2 publications, 2.44%
|
|
|
SLAS Discovery
2 publications, 2.44%
|
|
|
Expert Opinion on Drug Safety
2 publications, 2.44%
|
|
|
Expert Review of Hematology
2 publications, 2.44%
|
|
|
Bioorganic Chemistry
2 publications, 2.44%
|
|
|
Cells
1 publication, 1.22%
|
|
|
Frontiers in Pharmacology
1 publication, 1.22%
|
|
|
Oncotarget
1 publication, 1.22%
|
|
|
Dermatology
1 publication, 1.22%
|
|
|
Pharmaceuticals
1 publication, 1.22%
|
|
|
Frontiers in Molecular Biosciences
1 publication, 1.22%
|
|
|
Nature Reviews Clinical Oncology
1 publication, 1.22%
|
|
|
Interdisciplinary sciences, computational life sciences
1 publication, 1.22%
|
|
|
Nature Structural and Molecular Biology
1 publication, 1.22%
|
|
|
International Immunopharmacology
1 publication, 1.22%
|
|
|
Gene
1 publication, 1.22%
|
|
|
Seminars in Hematology
1 publication, 1.22%
|
|
|
Biochimica et Biophysica Acta - Reviews on Cancer
1 publication, 1.22%
|
|
|
Cancer Cell
1 publication, 1.22%
|
|
|
Cell
1 publication, 1.22%
|
|
|
Molecular Immunology
1 publication, 1.22%
|
|
|
Experimental Hematology
1 publication, 1.22%
|
|
|
Drug Discovery Today
1 publication, 1.22%
|
|
|
British Journal of Haematology
1 publication, 1.22%
|
|
|
Cancer Medicine
1 publication, 1.22%
|
|
|
1
2
3
|
Publishers
|
5
10
15
20
25
|
|
|
Elsevier
21 publications, 25.61%
|
|
|
Springer Nature
7 publications, 8.54%
|
|
|
Wiley
7 publications, 8.54%
|
|
|
Taylor & Francis
7 publications, 8.54%
|
|
|
Cold Spring Harbor Laboratory
6 publications, 7.32%
|
|
|
MDPI
5 publications, 6.1%
|
|
|
Frontiers Media S.A.
4 publications, 4.88%
|
|
|
American Chemical Society (ACS)
4 publications, 4.88%
|
|
|
American Association for Cancer Research (AACR)
3 publications, 3.66%
|
|
|
SAGE
2 publications, 2.44%
|
|
|
Impact Journals
1 publication, 1.22%
|
|
|
S. Karger AG
1 publication, 1.22%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 1.22%
|
|
|
Neoplasia Press
1 publication, 1.22%
|
|
|
Hindawi Limited
1 publication, 1.22%
|
|
|
National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation
1 publication, 1.22%
|
|
|
Oxford University Press
1 publication, 1.22%
|
|
|
The American Association of Immunologists
1 publication, 1.22%
|
|
|
Georg Thieme Verlag KG
1 publication, 1.22%
|
|
|
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 1.22%
|
|
|
Portland Press
1 publication, 1.22%
|
|
|
American Society of Hematology
1 publication, 1.22%
|
|
|
AME Publishing Company
1 publication, 1.22%
|
|
|
5
10
15
20
25
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
82
Total citations:
82
Citations from 2025:
15
(18.29%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Krönke J., Hurst S. N. Lenalidomide induces degradation of IKZF1 and IKZF3 // OncoImmunology. 2014. Vol. 3. No. 7. p. e941742.
GOST all authors (up to 50)
Copy
Krönke J., Hurst S. N. Lenalidomide induces degradation of IKZF1 and IKZF3 // OncoImmunology. 2014. Vol. 3. No. 7. p. e941742.
Cite this
RIS
Copy
TY - JOUR
DO - 10.4161/21624011.2014.941742
UR - https://doi.org/10.4161/21624011.2014.941742
TI - Lenalidomide induces degradation of IKZF1 and IKZF3
T2 - OncoImmunology
AU - Krönke, J.
AU - Hurst, Slater N
PY - 2014
DA - 2014/07/03
PB - Taylor & Francis
SP - e941742
IS - 7
VL - 3
PMID - 25610725
SN - 2162-4011
SN - 2162-402X
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2014_Krönke,
author = {J. Krönke and Slater N Hurst},
title = {Lenalidomide induces degradation of IKZF1 and IKZF3},
journal = {OncoImmunology},
year = {2014},
volume = {3},
publisher = {Taylor & Francis},
month = {jul},
url = {https://doi.org/10.4161/21624011.2014.941742},
number = {7},
pages = {e941742},
doi = {10.4161/21624011.2014.941742}
}
Cite this
MLA
Copy
Krönke, J., et al. “Lenalidomide induces degradation of IKZF1 and IKZF3.” OncoImmunology, vol. 3, no. 7, Jul. 2014, p. e941742. https://doi.org/10.4161/21624011.2014.941742.